Macrolide-based Regimens in Absence of Bacterial Co-infection in Critically Ill H1N1 Patients with Primary Viral Pneumonia

Overview

Journal Intensive Care Med

Specialty Critical Care

Date 2013 Jan 25

PMID 23344833

Citations 21

Authors

I Martin-Loeches

J F Bermejo-Martin

J Valles

R Granada

L Vidaur

J C Vergara-Serrano

M Martin

J C Figueira

J M Sirvent

J Blanquer

D Suarez

A Artigas

A Torres

E Diaz

A Rodriguez

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine whether macrolide-based treatment is associated with mortality in critically ill H1N1 patients with primary viral pneumonia.

Methods: Secondary analysis of a prospective, observational, multicenter study conducted across 148 Intensive Care Units (ICU) in Spain.

Results: Primary viral pneumonia was present in 733 ICU patients with pandemic influenza A (H1N1) virus infection with severe respiratory failure. Macrolide-based treatment was administered to 190 (25.9 %) patients. Patients who received macrolides had chronic obstructive pulmonary disease more often, lower severity on admission (APACHE II score on ICU admission (13.1 ± 6.8 vs. 14.4 ± 7.4 points, p < 0.05), and multiple organ dysfunction syndrome less often (23.4 vs. 30.1 %, p < 0.05). Length of ICU stay in survivors was not significantly different in patients who received macrolides compared to patients who did not (10 (IQR 4-20) vs. 10 (IQR 5-20), p = 0.9). ICU mortality was 24.1 % (n = 177). Patients with macrolide-based treatment had lower ICU mortality in the univariate analysis (19.2 vs. 28.1 %, p = 0.02); however, a propensity score analysis showed no effect of macrolide-based treatment on ICU mortality (OR = 0.87; 95 % CI 0.55-1.37, p = 0.5). Moreover, the sensitivity analysis revealed very similar results (OR = 0.91; 95 % CI 0.58-1.44, p = 0.7). A separate analysis of patients under mechanical ventilation yielded similar results (OR = 0.77; 95 % CI 0.44-1.35, p = 0.4).

Conclusion: Our results suggest that macrolide-based treatment was not associated with improved survival in critically ill H1N1 patients with primary viral pneumonia.

Citing Articles

Impact of Administering Intravenous Azithromycin within 7 Days of Hospitalization for Influenza Virus Pneumonia: A Propensity Score Analysis Using a Nationwide Administrative Database.

Tokito T, Kido T, Muramatsu K, Tokutsu K, Okuno D, Yura H Viruses. 2023; 15(5).

PMID: 37243228 PMC: 10222596. DOI: 10.3390/v15051142.

Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19.

Galindo-Oseguera E, Pinto-Almazan R, Arellano-Ramirez A, Gasca-Lopez G, Ocharan-Hernandez M, Calzada-Mendoza C Healthcare (Basel). 2023; 11(7).

PMID: 37046859 PMC: 10093873. DOI: 10.3390/healthcare11070932.

Hospital utilization rates for influenza and RSV: a novel approach and critical assessment.

Johnson E, Sylte D, Chaves S, Li Y, Mahe C, Nair H Popul Health Metr. 2021; 19(1):31.

PMID: 34126993 PMC: 8204427. DOI: 10.1186/s12963-021-00252-5.

Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.

Hache G, Rolain J, Gautret P, Deharo J, Brouqui P, Raoult D Microb Drug Resist. 2021; 27(3):281-290.

PMID: 33729874 PMC: 7987362. DOI: 10.1089/mdr.2020.0232.

Azithromycin in viral infections.

Oliver M, Hinks T Rev Med Virol. 2020; 31(2):e2163.

PMID: 32969125 PMC: 7536932. DOI: 10.1002/rmv.2163.

References

Brown R, Iannini P, Gross P, Kunkel M . Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest. 2003; 123(5):1503-11. DOI: 10.1378/chest.123.5.1503. View

Bermejo-Martin J, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramirez P . Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009; 13(6):R201. PMC: 2811892. DOI: 10.1186/cc8208. View

Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A . Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009; 13(5):R148. PMC: 2784367. DOI: 10.1186/cc8044. View

Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D . Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11(2):R31. PMC: 2206446. DOI: 10.1186/cc5713. View

Kumar A, Zarychanski R, Pinto R, Cook D, Marshall J, Lacroix J . Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009; 302(17):1872-9. DOI: 10.1001/jama.2009.1496. View

Martin-Loeches I, Sanchez-Corral A, Diaz E, Granada R, Zaragoza R, Villavicencio C . Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest. 2010; 139(3):555-562. DOI: 10.1378/chest.10-1396. View

Waterer G, Somes G, Wunderink R . Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001; 161(15):1837-42. DOI: 10.1001/archinte.161.15.1837. View

Bermejo-Martin J, Kelvin D, Eiros J, Castrodeza J, Ortiz de Lejarazu R . Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries. 2009; 3(3):159-61. DOI: 10.3855/jidc.18. View

Alfageme I, Aspa J, Bello S, Blanquer J, Blanquer R, Borderias L . [Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)]. Arch Bronconeumol. 2005; 41(5):272-89. PMC: 7131668. View

10.

Tahan F, Ozcan A, Koc N . Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2006; 29(1):91-7. DOI: 10.1183/09031936.00029206. View

11.

Baddour L, Yu V, Klugman K, Feldman C, Ortqvist A, Rello J . Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170(4):440-4. DOI: 10.1164/rccm.200311-1578OC. View

12.

Kim S, Hong S, Yun S, Choi W, Ahn J, Lee Y . Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011; 183(9):1207-14. DOI: 10.1164/rccm.201101-0110OC. View

13.

Mandell L, Wunderink R, Anzueto A, Bartlett J, Campbell G, Dean N . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. PMC: 7107997. DOI: 10.1086/511159. View

14.

Diaz E, Rodriguez A, Martin-Loeches I, Lorente L, Martin M, Pozo J . Impact of obesity in patients infected with 2009 influenza A(H1N1). Chest. 2010; 139(2):382-386. DOI: 10.1378/chest.10-1160. View

15.

Perez-Padilla R, Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E . Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009; 361(7):680-9. DOI: 10.1056/NEJMoa0904252. View

16.

Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. View

17.

Restrepo M, Mortensen E, Waterer G, Wunderink R, Coalson J, Anzueto A . Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2008; 33(1):153-9. DOI: 10.1183/09031936.00054108. View

18.

Viasus D, Pano-Pardo J, Cordero E, Campins A, Lopez-Medrano F, Villoslada A . Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect. 2011; 62(3):193-9. DOI: 10.1016/j.jinf.2011.01.014. View

19.

Martin-Loeches I, Lisboa T, Rhodes A, Moreno R, Silva E, Sprung C . Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2010; 37(2):272-83. PMC: 7079858. DOI: 10.1007/s00134-010-2078-z. View

20.

Rodriguez A, Mendia A, Sirvent J, Barcenilla F, De La Torre-Prados M, Sole-Violan J . Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007; 35(6):1493-8. DOI: 10.1097/01.CCM.0000266755.75844.05. View